Atossa Therapeutics, Inc.

NasdaqCM:ATOS Rapporto sulle azioni

Cap. di mercato: US$151.0m

Atossa Therapeutics Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Atossa Therapeutics ha un patrimonio netto totale di $73.7M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $79.5M e $5.8M.

Informazioni chiave

0%

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessin/a
ContantiUS$74.77m
Patrimonio nettoUS$73.68m
Totale passivitàUS$5.80m
Totale attivitàUS$79.48m

Aggiornamenti recenti sulla salute finanziaria

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Nov 12
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Jul 01
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Mar 07
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Nov 08
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Recent updates

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Nov 12
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go

Nov 08

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Jul 01
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Mar 07
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Nov 08
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Apr 26
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Jan 09
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Atossa Therapeutics: Still Gets An 'Incomplete' Rating

Oct 11

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Sep 25
We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Atossa Therapeutics GAAP EPS of -$0.05

Aug 08

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

May 12
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

A First Assessment On Atossa Therapeutics

Dec 10

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 02
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World

Sep 22

Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Jul 17
Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Atossa Therapeutics: Hope Springs Eternal

Jun 30

Atossa Therapeutics to be included in the Russell 2000, 3000 indexes

Jun 16

Atossa reaches a two-year high ahead of data readout for breast cancer therapy

Jun 07

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Apr 02
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Atossa updates on single-patient study for Endoxifen

Feb 04

Atossa halts Endoxifen breast cancer study after positive data

Feb 02

Atossa Therapeutics prices ~$25M direct offering, stock -23% PM

Jan 06

Atossa Therapeutics prices $14M registered direct offering

Dec 17

We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 10
We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Atossa Therapeutics plummets 38% after it raises $20M in public offering

Dec 09

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $77.1M ) di ATOS superano le sue passività a breve termine ( $5.8M ).

Passività a lungo termine: ATOS non ha passività a lungo termine.


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: ATOS è esente da debiti.

Riduzione del debito: ATOS non ha avuto debiti negli ultimi 5 anni.


Bilancio


Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: ATOS ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.

Previsione Cash Runway: ATOS ha una liquidità sufficiente per più di 3 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 16.6 % ogni anno


Scoprire le aziende sane